Regulation of transgene expression in muscles by ultrasound-mediated hyperthermia

Xu, Lisa X.; Zhao, Yupei; Zhang, Q; Li, Y; Xu, Yuhong

doi:10.1038/sj.gt.3302254

Cited by 25 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, its magnitude of induction depends on temperature as well as duration of the induced hyperthermia (11,12). Similar promoter characteristics were reported in vivo in a number of organs, such as skin (12), muscle (13), prostate (14), and liver (15), that were genetically modified using either a virus or a plasmid to express a reporter gene under the control of the HSP promoter. Noninvasive in vivo local heating, and thus local activation of gene expression, could be achieved with high-intensity focused ultrasound (HIFU) (15)(16)(17), but a subtle compromise has to be found in the heating strategy, because excessive tissue heating can induce tissue damage and necrosis.…”

mentioning

confidence: 70%

Image-guided, noninvasive, spatiotemporal control of gene expression

Deckers

Quesson

Arsaut

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

mentioning

confidence: 70%

Image-guided, noninvasive, spatiotemporal control of gene expression

Deckers

Quesson

Arsaut

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

“…They had studied enhanced GFP expression using a CMV promoter and they attributed the non-proportionality to the non-linear CMV promoter activity. This study did not specifically address multiple heat treatments to increase the duration of IL-12 production, but others have shown sustained high levels of luciferase expression with repeated hsp promoter induction [76]. These investigators did note a degree of thermotolerance where the subsequent heat treatment needed to be increased or delayed for maximal re-stimulation.…”

Section: Discussionmentioning

confidence: 94%

Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy

Siddiqui

Zhang

et al. 2006

International Journal of Hyperthermia

View full text Add to dashboard Cite

Interleukin-12 (IL-12) is a pro-inflammatory cytokine that has shown great promise as a therapeutic agent in experimental models of infectious disease and cancer. However, it is also a highly toxic molecule and for that reason has not been accepted readily into the clinic. A replication-deficient adenoviral vector was designed to deliver the feline interleukin-12 gene into tumour cells. The interleukin-12 gene has been placed under control of a heat inducible promoter, human heat shock promoter 70b, with the intent of spatially and temporally controlling the expression of IL-12, thus limiting its toxicity. In vitro, the transfection efficiency of the adenoviral vector, the effect of multiplicity of infection and the production of biologically active feline IL-12 were studied in the infected cells in response to a range of temperatures. This adenoviral vector will be a useful tool to examine the effects of intra-tumoural IL-12 delivery in a spontaneously occurring feline soft tissue sarcoma model.

show abstract

“…Gene expression systems incorporating the heat shock protein gene promoter have been evaluated for cancer gene therapy, with activation by simple application of local hyperthermia at tumour site to induce transgene expression [Huang et al, 2000;Li and Dewhirst, 2002]. This hyperthermia-inducible system has been employed to regulate plasmid transgene expression in muscle [Xu et al, 2004]. Up to 10 fold induction of luciferase reporter gene expression was confirmed following local application of ultrasound-mediated hyperthermia, in addition to the potential for reactivation on repeated treatment.…”

Section: Promoters Responsive To Physical or Physiological Stimulimentioning

confidence: 99%

Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?

Ratanamart¹,

Shaw²

2006

CGT

View full text Add to dashboard Cite

There is now conclusive evidence that gene therapy can lead to real clinical benefit. Initial enthusiasm has been muted by set-backs related to viral vectors including retroviral oncogenesis and adenoviral inflammatory response. Plasmid-mediated muscle-targeted gene transfer offers the potential of a cost-effective pharmaceutical grade therapy delivered by simple intramuscular injection without the need for anaesthetic, cell culture, transplantation or immunosuppression. This approach is particularly appropriate for long-term circulating therapeutic protein replacement currently requiring repeated injection therapy. Wide-ranging clinical applications include haemophilia, chronic anaemia, growth hormone deficiency and diabetes. Inadequate transgene expression, unregulated protein delivery and immune response have been major limiting factors. Recent innovations including in situ electroporation enabling sustained systemic protein delivery within the therapeutic range are reviewed. Pharmacological and physiological approaches to regulation are discussed in addition to the role of innate and humoral immunity. Translation of advances in all of these areas to clinical success will enable muscle-targeted gene therapy to capitalise on its inherent strengths and realise its long-standing promise.

show abstract

Regulation of transgene expression in muscles by ultrasound-mediated hyperthermia

Cited by 25 publications

References 25 publications

Image-guided, noninvasive, spatiotemporal control of gene expression

Image-guided, noninvasive, spatiotemporal control of gene expression

Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy

Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?

Contact Info

Product

Resources

About